不要因为痛而停止想念
Sometimes there is beauty in a pain that never goes away.
It is the capacity to feel consuming grief and pain and despair that also allows me to embrace love and joy and beauty with my whole heart. I must let it all in.
因为爱而感到幸福、因为爱而受过痛楚，爱与失去都是生命的一部分，当我们去爱，就会经历失去，如今回想起这一切，嘴角就能是上扬的。不需要任何的借口、任何的安慰，让伤痛成为自己的一部分，便是疗癒的开始。
~绘本《Hello Grief》
Sometimes there is beauty in a pain that never goes away.
It is the capacity to feel consuming grief and pain and despair that also allows me to embrace love and joy and beauty with my whole heart. I must let it all in.
因为爱而感到幸福、因为爱而受过痛楚，爱与失去都是生命的一部分，当我们去爱，就会经历失去，如今回想起这一切，嘴角就能是上扬的。不需要任何的借口、任何的安慰，让伤痛成为自己的一部分，便是疗癒的开始。
~绘本《Hello Grief》
若无其事
i me past can’t be
called back again，www[嘻嘻]填[笑cry]空[色]题[可爱]com The only thing we have to fear is fear itself？
SLove does not close,
and your long，Liwe，a good life meet slomy
今天出小区捡到了一万，抱着拾金不昧的精神，我在原地等失主等了很久，到了天黑都没等到，我就奇了怪了，那麻将缺了个一万还能打吗？
i me past can’t be
called back again，www[嘻嘻]填[笑cry]空[色]题[可爱]com The only thing we have to fear is fear itself？
SLove does not close,
and your long，Liwe，a good life meet slomy
今天出小区捡到了一万，抱着拾金不昧的精神，我在原地等失主等了很久，到了天黑都没等到，我就奇了怪了，那麻将缺了个一万还能打吗？
【美国FDA新药快讯】
美国FDA于2023年1月6日批准卫材公司（Eisai R&D Management Co., Ltd.）新药Leqembi(lecanemab-irmb)用于治疗阿兹海默病（早老性痴呆症），这是FDA批准的第2种直接针对阿兹海默病发病机制（基础病理生理学）的特效药物。
详见：https://t.cn/A69wbQ38
FDA NEWS RELEASE
FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
For Immediate Release:
January 06, 2023
Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer’s disease.
The FDA granted this application Fast Track, Priority Review and Breakthrough Therapy designations.
The approval of Leqembi was granted to Eisai R&D Management Co., Ltd. https://t.cn/R2WxRpI
美国FDA于2023年1月6日批准卫材公司（Eisai R&D Management Co., Ltd.）新药Leqembi(lecanemab-irmb)用于治疗阿兹海默病（早老性痴呆症），这是FDA批准的第2种直接针对阿兹海默病发病机制（基础病理生理学）的特效药物。
详见：https://t.cn/A69wbQ38
FDA NEWS RELEASE
FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
For Immediate Release:
January 06, 2023
Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer’s disease.
The FDA granted this application Fast Track, Priority Review and Breakthrough Therapy designations.
The approval of Leqembi was granted to Eisai R&D Management Co., Ltd. https://t.cn/R2WxRpI
✋热门推荐